



## ZB131 Clinical Trial: Information for Healthcare Providers

ZielBio is developing novel therapeutics to treat several forms of cancer and other serious diseases to meaningfully improve patients' lives. We conduct clinical trials to evaluate the efficacy of our promising therapies in patients with cancer who may benefit from them. Our clinicians follow strict scientific standards to protect patients.

ZielBio is currently recruiting people with certain types of advanced or metastatic cancers for the expansion stage of our Phase 1/2 trial evaluating our novel, investigational therapy, ZB131. Researchers are studying the safety of ZB131 and its ability to help people with solid tumors.

### About the ZB131 clinical trial

- **What is ZB131?**

ZB131 is a monoclonal antibody that binds to cancer cells with cancer-specific plectin (CSP) on their surface, inducing a form of programmed cell death.

- **Who is eligible for this study?**

This study is for people who meet the following eligibility criteria:

- Have advanced or metastatic pancreatic, ovarian, or bile duct cancer
- Are 18 years of age or older
- Have failed all available therapies or are ineligible for standard of care treatment

For a complete list of eligibility criteria, see [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05074472), identifier [NCT05074472](https://clinicaltrials.gov/ct2/show/study/NCT05074472).

- **What patients can expect**

- Potential participants will start with a screening visit to confirm their eligibility for the study. The staff at the trial site will take patients' medical history and perform a physical exam to ensure they meet the study requirements.
- ZB131 will be administered via IV every week at one of our trial sites.
- During study visits, participants will undergo tests and procedures in addition to those that are part of regular care for their type of cancer to study the treatment's effect.

### FAQs

- Are all participants guaranteed to receive ZB131 in this trial?
  - Yes.
- Do patients need to travel to participate in the study?
  - All participants will have to visit one of our study sites weekly for IV infusions of ZB131.
- Is there a cost to participating in this clinical trial?
  - The study drug ZB131 will be provided to participants at no cost. ZielBio will also cover all associated exams and reasonable travel costs. Participants will not receive other compensation.
- After enrolling in the clinical trial, can patients withdraw if they choose?



- Yes. Taking part in this clinical trial is voluntary and participation may be withdrawn at any point.
- Does ZielBio have an expanded use policy?
  - At this time, we are unable to provide ZB131 to patients outside the study.
- How can I learn more about this trial?
  - Email [clinical@zielbio.com](mailto:clinical@zielbio.com) or contact one of our sites below for more information.

## Trial sites

The following sites are currently recruiting participants for the ZB131 trial. If you believe your patient may be a good fit for the ZB131 trial, please contact the site most convenient to the patient for more information.

State	City	Site	Contact	Status
United States, AZ	Phoenix, Arizona, United States, 85054	Mayo Clinic - Phoenix	Clinical Trials Referral Office 855-776-0015	<b>Recruiting</b>
United States, FL	Jacksonville, Florida, United States, 32224	Mayo Clinic - Jacksonville	Clinical Trials Referral Office 855-776-0015	<b>Recruiting</b>
United States, MN	Rochester, Minnesota, United States, 55905	Mayo Clinic - Rochester	Clinical Trials Referral Office 855-776-0015	<b>Recruiting</b>
United States, TN	Nashville, Tennessee, United States, 37203	Sarah Cannon Research Institute	Sarah Cannon, <a href="mailto:asksarah@sarahcannon.com">asksarah@sarahcannon.com</a>	<b>Recruiting</b>
United States, TX	Austin, Texas, United States, 78758	NEXT Oncology	Cynthia DeLeon, 210-580-9521, <a href="mailto:cdeleon@nextoncology.com">cdeleon@nextoncology.com</a>	<b>Recruiting</b>
United States, TX	San Antonio, Texas, United States, 78229	NEXT Oncology	Cynthia DeLeon, 210-580-9521, <a href="mailto:cdeleon@nextoncology.com">cdeleon@nextoncology.com</a>	<b>Recruiting</b>
United States, TX	Houston, Texas, 77030	MD Anderson Cancer Center	Rabia Khan, 713-563-4667 , <a href="mailto:RKhan@mdanderson.org">RKhan@mdanderson.org</a>	<b>Recruiting</b>
United States, VA	Charlottesville, Virginia, United States, 22908	University of Virginia	Ralph Watson, <a href="mailto:uvacancertrials@hscmail.mcc.virginia.edu">uvacancertrials@hscmail.mcc.virginia.edu</a>	<b>Recruiting</b>
United States, VA	Fairfax, Virginia, United States, 22031	NEXT Oncology	Frances Gatlin, 210-580-9500, <a href="mailto:fgatlin@nextoncology.com">fgatlin@nextoncology.com</a>	<b>Recruiting</b>